Resources Repository
-
Resource PortalWeb Portal, Teaching Resource 2024ImmunizationEconomics.org
ImmunizationEconomics.org is a resource for organizations and individuals involved in the field of immunization economics. …
ImmunizationEconomics.org is a resource for organizations and individuals involved in the field of immunization economics. The site was originally created in 2015 as part of the EPIC project with funding from the Bill & Melinda Gates Foundation and has key collaborators from the Harvard T.H. Chan School of Public Health, Johns Hopkins University, ThinkWell, and Results for Development. ImmunizationEconomics.org has three central aims: (1) To create a global community of practice consisting of experts in…
Cost-Effectiveness Analysis | Infectious Diseases | Costing Methods | Health Systems | Health/Medicine | Global -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Cost-Effectiveness Analysis | Infectious Diseases | Costing Methods | Mathematical Models | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Dynamic Transmission | Infectious Diseases | Mathematical Models | Child/Nutrition | Health Systems | Global Governance | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Identifying Cost-Effective Dynamic Policies to Control Epidemics
This paper describes a mathematical decision model for identifying dynamic health policies for controlling epidemics. …
This paper describes a mathematical decision model for identifying dynamic health policies for controlling epidemics. The dynamic policies aim to select the best current intervention based on accumulating epidemic data and the availability of resources at each decision point. An algorithm is proposed to approximate dynamic policies that optimize the population's net health benefit, a performance measure which accounts for both health and monetary outcomes. The authors further illustrate how dynamic policies can be defined and…
Cost-Effectiveness Analysis | Dynamic Transmission | Infectious Diseases | Mathematical Models | Dynamic Simulation | Health/Medicine -
ArticlePublication 2016Rotavirus Vaccines Contribute Towards UHC in A Mixed Public–Private Healthcare System
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from …
This extended cost-effectiveness analysis (ECEA) evaluates the non-health benefits of rotavirus vaccination in Malaysia from the household’s perspective. The authors found that rotavirus vaccination reduces rotavirus episodes and expenditure substantially and provides financial risk protection to all income groups. Although the rich are paying more out of pocket than the poor by utilizing more expensive healthcare, the poor are paying more in proportion to household income. Poverty reduction benefits are concentrated amongst the poorest two…
Cost-Effectiveness Analysis | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Child/Nutrition | Social Determinants | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Asia & Pacific -
ArticlePublication 2016What Determines HIV Prevention Costs at Scale?
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, …
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, funding for HIV prevention remains scarce, and there are growing calls internationally to improve the efficiency of HIV prevention programmes as a key strategy to reach global HIV targets. To date, there is limited evidence on the determinants of costs of HIV prevention delivered through NGOs, and thus, policymakers have little guidance in how best to design programmes that are…
Cost-Effectiveness Analysis | Infectious Diseases | Costing Methods | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Asia & Pacific -
ReviewPublication 2016Dynamic Transmission Economic Evaluation of Infectious Disease in LMIC
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious …
Economic evaluation using dynamic transmission models is important for capturing the indirect effects of infectious disease interventions. The authors examine the use of these methods in low- and middle-income countries, where infectious diseases constitute a major burden. The review is comprised of two parts: (1) a summary of dynamic transmission economic evaluations across all disease areas published between 2011 and mid-2014 and (2) an in-depth review of mosquito-borne disease studies focusing on health economic methods…
Cost-Effectiveness Analysis | Dynamic Transmission | Infectious Diseases | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Using Top-Down and Bottom-Up Costing Approaches in LMICs
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel …
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is a methodologically challenging and substantial empirical undertaking. Using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance to riframpicin (RIF) in South Africa, the authors estimate costs, by applying two distinct approaches of bottom-up and top-down costing, together with an assessment of processes and capacity. The unit costs measured using the…
Cost-Effectiveness Analysis | Infectious Diseases | Costing Methods | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Priority Setting/Ethics | Chronic Disease/Risk | Mental Health | Health Systems | Economics/Finance | Health/Medicine | Global